[go: up one dir, main page]

WO2006116755A3 - Effets synergiques de l'acide docosahexaenoique (dha) et de l'absorbtion de carotenoides sur les fonctions cognitives - Google Patents

Effets synergiques de l'acide docosahexaenoique (dha) et de l'absorbtion de carotenoides sur les fonctions cognitives Download PDF

Info

Publication number
WO2006116755A3
WO2006116755A3 PCT/US2006/016506 US2006016506W WO2006116755A3 WO 2006116755 A3 WO2006116755 A3 WO 2006116755A3 US 2006016506 W US2006016506 W US 2006016506W WO 2006116755 A3 WO2006116755 A3 WO 2006116755A3
Authority
WO
WIPO (PCT)
Prior art keywords
dha
docosahexaenoic acid
synergitic
effects
cognitive function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/016506
Other languages
English (en)
Other versions
WO2006116755A2 (fr
Inventor
Elizabeth J Johnson
Donald Max Snodderly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of WO2006116755A2 publication Critical patent/WO2006116755A2/fr
Publication of WO2006116755A3 publication Critical patent/WO2006116755A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur des préparations pharmaceutiques et des méthodes accroissant l'absorption de caroténoïdes diététiques par l'homme, et susceptibles de ralentir réduire ou prévenir l'apparition de troubles neurologiques ou de mémoire; et d'améliorer l'apprentissage, la cognition, et l'acquisition et la rétention d'éléments par la mémoire. Lesdites préparations pharmaceutiques consistent en doses à effet thérapeutique et/ou prophylactique de lutéine et d'acide docosahexaénoïque (DHA).
PCT/US2006/016506 2005-04-28 2006-04-28 Effets synergiques de l'acide docosahexaenoique (dha) et de l'absorbtion de carotenoides sur les fonctions cognitives Ceased WO2006116755A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67594805P 2005-04-28 2005-04-28
US60/675,948 2005-04-28

Publications (2)

Publication Number Publication Date
WO2006116755A2 WO2006116755A2 (fr) 2006-11-02
WO2006116755A3 true WO2006116755A3 (fr) 2007-03-15

Family

ID=37215591

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/016506 Ceased WO2006116755A2 (fr) 2005-04-28 2006-04-28 Effets synergiques de l'acide docosahexaenoique (dha) et de l'absorbtion de carotenoides sur les fonctions cognitives

Country Status (1)

Country Link
WO (1) WO2006116755A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829126B2 (en) 2005-10-26 2010-11-09 Abbott Laboratories Infant formulas containing docosahexaenoic acid and lutein
US20070166354A1 (en) 2005-10-26 2007-07-19 Bridget Barrett-Reis Method of reducing the risk of retinopathy of prematurity in preterm infants
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
US7790688B2 (en) 2008-01-11 2010-09-07 Healthspan Solutions, Llc Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly
US8716249B2 (en) 2008-01-31 2014-05-06 Energy Light Llc Compositions and methods for improving cardiovascular health
JP2012516852A (ja) * 2009-02-02 2012-07-26 マーテック バイオサイエンシーズ コーポレーション 認知機能改善および心拍数低下のための方法
US20110177061A1 (en) * 2009-07-10 2011-07-21 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid
US20130011469A1 (en) 2009-07-23 2013-01-10 U.S. Nutraceuticals, Llc D/B/A Valensa International Krill oil and carotenoid composition, associated method and delivery system
US20130295171A1 (en) 2009-07-23 2013-11-07 U.S NUTRACEUTICALS, LLC d/b/a Valensa International Krill oil and reacted astaxanthin composition and associated method
MX2012004777A (es) * 2009-10-30 2012-06-01 Nestec Sa Metodos para mantener la salud de los ojos y mejorar enfermedades oftalmicas en caninos.
MX353505B (es) * 2009-11-09 2018-01-17 Dsm Ip Assets B V Star Uso de composiciones que contienen luteina para mejorar ciertos aspectos de la memoria.
EP2531184A1 (fr) * 2010-02-02 2012-12-12 Soluciones Extractivas Alimentarias S.L. (Solutex) Esters éthyliques de l'acide docosahexaénoïque et/ou leurs dérivés pour la prévention et/ou le traitement de la dégénérescence maculaire liée à l'âge
US20110200644A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Ester Emulsions
WO2013086330A1 (fr) * 2011-12-08 2013-06-13 Abbott Laboratories Compositions nutritionnelles comprenant de la curcumine et de l'acide docosahexaénoïque pour l'amélioration de la cognition
DE212013000066U1 (de) * 2012-07-19 2014-09-25 U.S. Nutraceuticals Llc Dba Valensa International Krillöl und reagierte Astaxanthinzusammensetzung
JP6375296B2 (ja) * 2013-07-10 2018-08-15 ライオン株式会社 脳機能改善用内服組成物、脳内アミロイドβ蓄積抑制用内服組成物、脳機能改善用食品組成物及び脳内アミロイドβ蓄積抑制用食品組成物
EP3585369A4 (fr) * 2017-02-22 2020-08-26 Cargill, Incorporated Purification d'huiles contenant du dha
NL2019436B1 (en) * 2017-08-23 2019-03-07 Newtricious Bv Composition comprising a xantophyll and an omega-3 fatty acid and method of use thereof
GB201720119D0 (en) * 2017-12-04 2018-01-17 Howard Foundation Holdings Ltd Prevention and/or treatment of neurodegenerative disease
SG10201900604TA (en) * 2019-01-23 2020-08-28 Agency For Science Technology And Research Astarstar Pre-natal beta-cryptoxanthin benefits children
CN116621749A (zh) * 2023-05-24 2023-08-22 中国海洋大学 一种护眼dha-叶黄素酯及其制备方法、应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002992A1 (en) * 2003-06-17 2005-01-06 Mccleary Edward Larry Foods, beverages, condiments, spices and salad dressings with specialized supplements

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002992A1 (en) * 2003-06-17 2005-01-06 Mccleary Edward Larry Foods, beverages, condiments, spices and salad dressings with specialized supplements

Also Published As

Publication number Publication date
WO2006116755A2 (fr) 2006-11-02

Similar Documents

Publication Publication Date Title
WO2006116755A3 (fr) Effets synergiques de l'acide docosahexaenoique (dha) et de l'absorbtion de carotenoides sur les fonctions cognitives
WO2004112776A3 (fr) Traitement d'une maladie inflammatoire
AU2003253816A1 (en) Epa and dha enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
WO2009013596A3 (fr) Enrichissement de produits nutritionnels avec des extraits d'olive contenant de l'hydroxytyrosol, et produits nutritionnels enrichis en hydroxytyrosol
WO2005110375A8 (fr) Supplément alimentaire pour le traitement des maladies oculaires
IL172621A0 (en) Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2009012871A3 (fr) Capsule filtrant les uv
WO2008028631A3 (fr) Composition de soin de la peau
EP2168570A3 (fr) Extraits d'isochrysis sp.
CA2529735A1 (fr) Composition pour la prevention et le traitement des varices des membres inferieures
WO2006086707A3 (fr) Extraits de plantes de la famille des asteraceae contenant des niveaux reduits de derives de thiophenes phototoxiques et procedes de preparation desdits extraits
EP2486793A3 (fr) Formulations d'acide S-(+)-abscissique sous forme de liquide ou de granulé soluble
WO2006115412A3 (fr) Nutrition avec des lipides et des saccharides non digestibles
PL371853A1 (en) Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis
EP2615091A3 (fr) Formes solides comprenant des compositions 4- [9-(3S)-(tetrahydro-furan-3-yl) -8- (2,4,6-trifluoro-phénylamino) -9H-purin-2-ylamino]-trans-cyclohexan-1-ol, compositions correspondantes et utilisations de celles-ci
WO2006104610A3 (fr) Transcarotenoides et leur synthese, leur preparation et leurs utilisations
WO2007036363A3 (fr) Ester d'acide butyrique d'hydrate de carbone et de polyols d'hydrate de carbone
WO2012013331A3 (fr) Capsules d'ingrédients pharmaceutiques actifs et d'acides gras polyinsaturés pour le traitement de maladies de la prostate
WO2011097276A8 (fr) Procédés et compositions pour traiter l'arthrite par de l'acide docosahexaénoïque
WO2006002909A3 (fr) Compositions pharmaceutiques derivees de sphingolipides
WO2008025819A3 (fr) Formulations de l'acide acétylsalicylique ou de ses dérivés dans des capsules molles, présentant une stabilité élevée
EP2503341A3 (fr) Modulateurs de la régénération neuronale
WO2007147899A3 (fr) Esters de dha et leur utilisation dans le traitement et la prévention d'une maladie cardiovasculaire
WO2005027977A3 (fr) Compositions de diclofenac destinees au traitement d'affections cutanees
IL164089A0 (en) Astaxanthin medium-chain fatty acidester, production method of the same, and composition comprising the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06758808

Country of ref document: EP

Kind code of ref document: A2